Harnessing our unparalleled expertise
We have over thirty years of experience in complex carbohydrate & polymer chemistry, and over two decades of ICH Q7-equivalent cGMP manufacture.
We apply our exceptional expertise in R&D, synthetic route development, scale-up synthesis and analytical method development to a range of pharmaceutical research areas in order to support current good manufacturing process (cGMP).
Our team has more than three decades of experience in complex carbohydrate and polymer chemistry. We have a long track record of delivering of drug compounds and data resulting in successful Investigational New Drug (IND) submissions for pre-clinical and clinical trials.
We have worked in ICH Q7-equivalent cGMP manufacture for over twenty years.
We’re experts in
- Complex Carbohydrates
- Polymers
- Dendrimers
- Glycolipids
- Nucleoside Analogs
- Vaccine adjuvants
Polymers, Glycopolymers, and Dendrimers
GlycoSyn has extensive experience in the manufacture of high quality cGMP polymeric scaffolds, which have garnered successful IND submissions.
This includes a successful IND with US FDA for the first discrete dendrimer construct, as well as multiple polymers currently in PI to III clinical trials.
Process development & redevelopment
Our considerable process development expertise helps our clients boost the efficiency and reliability of their synthetic processes for both small and large molecules.
Rare disease market
We are working with some of the world’s largest orphan drug companies to manufacture cGMP-grade commercial ingredients, advanced intermediates, and small molecule drugs/therapeutics.
Drug Metabolites
We carry out enzymatic glucuronidation reactions on compounds in a way that mimics the processes occurring naturally in our bodies. We then purify the resultant products for use as analytical standards.
We have experience in production of glucuronides from milligram to gram scale using either synthetic or enzymatic methodologies.
“IP is weightless and drug compound manufacture is often small-scale, so geographical location is no longer a barrier to global development. Our clients’ have access to leading international researchers and their precious intellectual property is well protected in our New Zealand-based research laboratories and ICH Q7-equivalent cGMP manufacturing facilities.
We are also able to apply our small molecule carbohydrate expertise across a wide range of pharmaceutical research areas from orphan drug development to complex custom glycan arrays, biomarkers and the creation of exacting analytical standards”
Richard Lauricella,
Business Development Manager, USA